menu
    • menu

    Company profile for Rznomics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Rznomics was founded in 2017 and is based in Yongin-si, South Korea.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Rznomicskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    #801, Innovalley C-dong, 253, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do ...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.rznomics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly strengthens RNA pipeline with $1.3B hearing loss pact
    Lilly strengthens RNA pipeline with $1.3B hearing loss pact

    17 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lilly-strengthens-rna-pipeline-13b-biobucks-hearing-loss-pact

    FIERCE BIOTECH
    17 May 2025
    Share Share
    Rznomics Liver Cancer Drug Secures Fast Track Designation
    Rznomics Liver Cancer Drug Secures Fast Track Designation

    18 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rznomics-inc-liver-cancer-drug-candidate-secures-fast-track-designation-302378530.html

    PR NEWSWIRE
    18 Feb 2025
    Share Share
    Rznomics Secures Expanded Access Program for Glioblastoma Patients
    Rznomics Secures Expanded Access Program for Glioblastoma Patients

    25 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rznomics-announces-to-secure-the-expanded-access-program-for-patients-with-glioblastoma-gbm-302315107.html

    PR NEWSWIRE
    25 Nov 2024
    Share Share
    SK Pharmteco And Rznomics Explore RNA Gene Therapy Collaboration
    SK Pharmteco And Rznomics Explore RNA Gene Therapy Collaboration

    05 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sk-pharmteco-and-rznomics-explore-collaboration-for-rna-based-gene-therapy-development-and-manufacturing-302213313.html

    PR NEWSWIRE
    05 Aug 2024
    Share Share
    Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ-001
    Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ-001

    02 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rznomics-inc-secures-orphan-drug-designation-from-fda-for-rz-001-in-hepatocellular-carcinoma-302051867.html

    PR NEWSWIRE
    02 Feb 2024
    Share Share
    Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001
    Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001

    10 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rznomics-inc-secures-fast-track-designation-from-the-us-fda-for-rz-001-301984712.html

    PR NEWSWIRE
    10 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search